Table 1.
Demographic and baseline characteristics
| Characteristic | OROS hydromorphone ER (N = 447) |
|---|---|
| Age, years | |
| Mean (SD) | 49.0 (10.43) |
| Age group, n (%) | |
| 18–64 years | 420 (94.0) |
| 65–75 years | 27 (6.0) |
| Sex, n (%) | |
| Male | 227 (50.8) |
| Race, n (%) | |
| Caucasian | 383 (85.7) |
| Black | 37 (8.3) |
| Other | 27 (6.0) |
| Weight, kg | |
| Mean (SD) | 90.33 (23.35) |
| Height, cm | |
| Mean (SD) | 170.95 (10.75) |
| Body mass index, kg/m2 | |
| Mean (SD) | 30.85 (7.36) |
| Etiology, n (%) | |
| Non-neuropathic low back paina | 276 (61.7) |
| Neuropathic low back painb | 167 (37.4) |
| Missing | 4 (0.9) |
| Prior opioid, n (%) | |
| Hydrocodone | 151 (33.8) |
| Oxycodone | 123 (27.5) |
| Morphine | 73 (16.3) |
| Fentanyl | 26 (5.8) |
| Methadone | 25 (5.6) |
| Tramadol | 22 (4.9) |
| Propoxyphene | 8 (1.8) |
| Hydromorphone | 8 (1.8) |
| Oxymorphone | 7 (1.6) |
Notes:
a
Class 1 or 2 based on the Quebec Task Force Classification of Spinal Disorders;
b
class 3, 4, 5, or 6 based on the Quebec Task Force Classification of Spinal Disorders.
Abbreviations: ER, extended release; N, total number; SD, standard deviation.